{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:29:16Z","timestamp":1791660556007,"version":"4.3.4"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/S003118\/1"],"award-info":[{"award-number":["MR\/S003118\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR301690"],"award-info":[{"award-number":["NIHR301690"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.psychres.2025.116406","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T11:10:38Z","timestamp":1739790638000},"page":"116406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A systematic review and synthesis of 489 studies investigating treatments for negative symptoms in the schizophrenia spectrum: Trial designs, demographics and clinical characteristics"],"prefix":"10.1016","volume":"347","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5235-0788","authenticated-orcid":false,"given":"Stefano","family":"Damiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"D'Imperio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Radua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6778-2316","authenticated-orcid":false,"given":"Lydia","family":"Fortea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Cal\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia Maria","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7086-6867","authenticated-orcid":false,"given":"Estella Linda Luisa","family":"Lumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Patron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5658-5527","authenticated-orcid":false,"given":"Alessandro","family":"Peviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Provenzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Santilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Spallarossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5847-6947","authenticated-orcid":false,"given":"Laura","family":"Fusar-Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8029-666X","authenticated-orcid":false,"given":"Evangelos","family":"Papanastasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9259-8788","authenticated-orcid":false,"given":"Rashmi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Galderisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-4352","authenticated-orcid":false,"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fusar-Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.psychres.2025.116406_bib0001","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00406-016-0697-2","article-title":"Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia","volume":"266","author":"an der Heiden","year":"2016","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"12","key":"10.1016\/j.psychres.2025.116406_bib0002","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1038\/sj.npp.1300796","article-title":"Amoxapine as an atypical antipsychotic: a comparative study vs risperidone","volume":"30","author":"Apiquian","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.psychres.2025.116406_bib0003","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Multiple fixed doses of ''Seroquel'' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo","volume":"42","author":"Arvanitis","year":"1997","journal-title":"Biol. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.psychres.2025.116406_bib0004","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0920-9964(01)00402-9","article-title":"Computer-assisted cognitive rehabilitation reduces negative symptoms in the severely mentally ill","volume":"59","author":"Bellucci","year":"2003","journal-title":"Schizophr. Res."},{"issue":"203","key":"10.1016\/j.psychres.2025.116406_bib0005","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1080\/01621459.1938.10502329","article-title":"Some difficulties of interpretation encountered in the application of the chi-square test","volume":"33","author":"Berkson","year":"1938","journal-title":"J. Am. Stat. Assoc."},{"issue":"3","key":"10.1016\/j.psychres.2025.116406_bib0006","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/schbul\/sbz090","article-title":"Are randomized controlled trials on pharmacotherapy and psychotherapy for positive symptoms of schizophrenia comparable? A systematic review of patient and study characteristics","volume":"46","author":"Bighelli","year":"2020","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.psychres.2025.116406_bib0007","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00004714-199604000-00008","article-title":"ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia","volume":"16","author":"Borison","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2025.116406_bib0008","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.psychres.2018.12.026","article-title":"From cognitive and clinical substrates to functional profiles: disentangling heterogeneity in schizophrenia","volume":"271","author":"Bosia","year":"2019","journal-title":"Psychiatry Res."},{"issue":"7","key":"10.1016\/j.psychres.2025.116406_bib0009","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.euroneuro.2014.03.007","article-title":"A phase II\/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - Results from the CandleLyte study","volume":"24","author":"Bugarski-Kirola","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2025.116406_bib0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cpr.2016.11.009","article-title":"Cognitive remediation for negative symptoms of schizophrenia: a network meta-analysis","volume":"52","author":"Cella","year":"2017","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.psychres.2025.116406_bib0011","first-page":"1","article-title":"Psychosocial and behavioural interventions for the negative symptoms of schizophrenia: a systematic review of efficacy meta-analyses","author":"Cella","year":"2023","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116406_bib0012","series-title":"Statistical Power Analysis For the Behavioral Sciences","author":"Cohen","year":"2013"},{"issue":"4","key":"10.1016\/j.psychres.2025.116406_bib0013","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00006199-200307000-00008","article-title":"Grey literature in meta-analyses","volume":"52","author":"Conn","year":"2003","journal-title":"Nurs. Res."},{"issue":"4","key":"10.1016\/j.psychres.2025.116406_bib0014","doi-asserted-by":"crossref","first-page":"FNL52","DOI":"10.2217\/fnl-2020-0012","article-title":"Cariprazine in the management of negative symptoms of schizophrenia: state of the art and future perspectives","volume":"15","author":"Correll","year":"2020","journal-title":"Future Neurol."},{"key":"10.1016\/j.psychres.2025.116406_bib0015","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment","author":"Correll","year":"2020","journal-title":"Neuropsychiatr. Dis. Treatm."},{"issue":"3","key":"10.1016\/j.psychres.2025.116406_bib0016","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1370\/afm.2676","article-title":"Psychologic treatment of depression compared with pharmacotherapy and combined treatment in primary care: a network meta-analysis","volume":"19","author":"Cuijpers","year":"2021","journal-title":"Ann. Fam. Med."},{"issue":"6 Suppl 1","key":"10.1016\/j.psychres.2025.116406_bib0017","doi-asserted-by":"crossref","first-page":"6S18","DOI":"10.1016\/S0013-7006(16)30005-7","article-title":"Negative symptoms, emotion and cognition in schizophrenia","volume":"41","author":"Fakra","year":"2015","journal-title":"L'encephale"},{"issue":"5","key":"10.1016\/j.psychres.2025.116406_bib0019","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/cap.2011.0092","article-title":"Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial","volume":"22","author":"Findling","year":"2012","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.psychres.2025.116406_bib0020","series-title":"DSM-5\u00ae Handbook of Differential Diagnosis","author":"First","year":"2013"},{"issue":"5","key":"10.1016\/j.psychres.2025.116406_bib0021","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.euroneuro.2013.10.017","article-title":"Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders","volume":"24","author":"Foussias","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.psychres.2025.116406_bib0022","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/schbul\/sbu170","article-title":"Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials","volume":"41","author":"Fusar-Poli","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.psychres.2025.116406_bib0023","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1192\/j.eurpsy.2021.13","article-title":"EPA guidance on treatment of negative symptoms in schizophrenia","volume":"64","author":"Galderisi","year":"2021","journal-title":"Eur. Psych."},{"issue":"8","key":"10.1016\/j.psychres.2025.116406_bib0024","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S2215-0366(18)30050-6","article-title":"Negative symptoms of schizophrenia: new developments and unanswered research questions","volume":"5","author":"Galderisi","year":"2018","journal-title":"Lancet Psych."},{"issue":"1","key":"10.1016\/j.psychres.2025.116406_bib0025","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1192\/j.eurpsy.2021.11","article-title":"EPA guidance on assessment of negative symptoms in schizophrenia","volume":"64","author":"Galderisi","year":"2021","journal-title":"Eur. Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2025.116406_bib0026","first-page":"466","article-title":"Token reinforcement therapeutic approach is more effective than exercise for controlling negative symptoms of schizophrenic patients: a randomized controlled trial","volume":"3","author":"Gholipour","year":"2012","journal-title":"Int. J. Prev. Med."},{"issue":"3","key":"10.1016\/j.psychres.2025.116406_bib0027","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3102\/00028312003003187","article-title":"Testing homogeneity of variances","volume":"3","author":"Glass","year":"1966","journal-title":"Am. Educ. Res. J."},{"issue":"6","key":"10.1016\/j.psychres.2025.116406_bib0028","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/cap.2008.0144","article-title":"A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia","volume":"19","author":"Haas","year":"2009","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2025.116406_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12874-017-0347-z","article-title":"Grey literature in systematic reviews: a cross-sectional study of the contribution of non-English reports, unpublished studies and dissertations to the results of meta-analyses in child-relevant reviews","volume":"17","author":"Hartling","year":"2017","journal-title":"BMC Med. Res. Methodol."},{"issue":"2","key":"10.1016\/j.psychres.2025.116406_bib0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3102\/10769986006002107","article-title":"Distribution theory for Glass's estimator of effect size and related estimators","volume":"6","author":"Hedges","year":"1981","journal-title":"J. Educ. Stat."},{"issue":"11\u201312","key":"10.1016\/j.psychres.2025.116406_bib0031","first-page":"54","article-title":"Understanding antipsychotic drug treatment effects: a novel method to reduce pseudospecificity of the positive and negative syndrome scale (PANSS) factors","volume":"14","author":"Hopkins","year":"2017","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.psychres.2025.116406_bib0032","first-page":"1","article-title":"Treating negative symptoms of schizophrenia: current approaches and future perspectives","author":"Howes","year":"2023","journal-title":"Br. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2025.116406_bib0033","doi-asserted-by":"crossref","first-page":"S409","DOI":"10.4103\/0019-5545.116318","article-title":"Effect of yoga therapy on plasma oxytocin and facial emotion recognition deficits in patients of schizophrenia","volume":"55","author":"Jayaram","year":"2013","journal-title":"India J. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2025.116406_bib0034","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0447.2012.01911.x","article-title":"Predictors of medication adherence in patients with schizophrenia and bipolar disorder","volume":"127","author":"J\u00f3nsd\u00f3ttir","year":"2013","journal-title":"Acta Psychiatr. Scand."},{"issue":"10","key":"10.1016\/j.psychres.2025.116406_bib0035","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/archpsyc.58.10.965","article-title":"Clozapine and haloperidol in moderately refractory schizophrenia - a 6-month randomized and double-blind comparison","volume":"58","author":"Kane","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2025.116406_bib0036","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00406-020-01220-0","article-title":"Enhancement of aerobic fitness improves social functioning in individuals with schizophrenia","volume":"271","author":"Kimhy","year":"2021","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"5","key":"10.1016\/j.psychres.2025.116406_bib0037","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1017\/S1352465813000258","article-title":"Cognitive behaviour therapy for psychotic symptoms: a randomized controlled effectiveness trial","volume":"41","author":"Krakvik","year":"2013","journal-title":"Behav. Cogn. Psychother."},{"key":"10.1016\/j.psychres.2025.116406_bib0038","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00406-018-0869-3","article-title":"Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis","volume":"268","author":"Krause","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"260","key":"10.1016\/j.psychres.2025.116406_bib0039","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/01621459.1952.10483441","article-title":"Use of ranks in one-criterion variance analysis","volume":"47","author":"Kruskal","year":"1952","journal-title":"J. Am. Stat. Assoc."},{"issue":"5","key":"10.1016\/j.psychres.2025.116406_bib0040","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.biopsych.2007.04.043","article-title":"Clozapine and \"high-dose\" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison","volume":"63","author":"Kumra","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116406_bib0041","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3389\/fpsyg.2013.00863","article-title":"Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs","volume":"4","author":"Lakens","year":"2013","journal-title":"Front. Psychol."},{"key":"10.1016\/j.psychres.2025.116406_bib0042","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.euroneuro.2021.02.008","article-title":"Neurocognitive functions in persistent negative symptoms following a first episode of psychosis","volume":"47","author":"Lepage","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.psychres.2025.116406_bib0043","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1192\/bjp.bp.111.096594","article-title":"Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses","volume":"200","author":"Leucht","year":"2012","journal-title":"Br. J. Psychiatry"},{"issue":"9831","key":"10.1016\/j.psychres.2025.116406_bib0044","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.psychres.2025.116406_bib0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/bjc.12147","article-title":"Gender differences in preferences for psychological treatment, coping strategies, and triggers to help-seeking","volume":"57","author":"Liddon","year":"2018","journal-title":"Brit. J. Clin. Psychol."},{"issue":"2","key":"10.1016\/j.psychres.2025.116406_bib0046","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/JCP.0000000000000071","article-title":"The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia a proof-of-principle study","volume":"34","author":"Litman","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.psychres.2025.116406_bib0047","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1037\/ccp0000599","article-title":"Mobile enhancement of motivation in schizophrenia: a pilot randomized controlled trial of a personalized text message intervention for motivation deficits","volume":"88","author":"Luther","year":"2020","journal-title":"J. Consult. Clin. Psychol."},{"issue":"1","key":"10.1016\/j.psychres.2025.116406_bib0048","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/wps.20809","article-title":"The clinical characterization of the patient with primary psychosis aimed at personalization of management","volume":"20","author":"Maj","year":"2021","journal-title":"World Psych."},{"issue":"5","key":"10.1016\/j.psychres.2025.116406_bib0049","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/08039480801959307","article-title":"Negative symptoms in schizophrenia: a review","volume":"62","author":"M\u00e4kinen","year":"2008","journal-title":"Nord. J. Psych."},{"issue":"1","key":"10.1016\/j.psychres.2025.116406_bib0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/wps.20385","article-title":"The current conceptualization of negative symptoms in schizophrenia","volume":"16","author":"Marder","year":"2017","journal-title":"World Psych."},{"issue":"3","key":"10.1016\/j.psychres.2025.116406_bib0051","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/10503307.2017.1411628","article-title":"Cochrane's risk of bias tool in the context of psychotherapy outcome research","volume":"28","author":"Munder","year":"2018","journal-title":"Psychother. Res."},{"key":"10.1016\/j.psychres.2025.116406_bib0052","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.schres.2022.12.051","article-title":"Community-based multi-site randomized controlled trial of behavioral activation for patients with negative symptoms of schizophrenia","volume":"252","author":"Oh","year":"2023","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2025.116406_bib0053","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4028\/www.scientific.net\/AMM.611.115","article-title":"Methodology and application of the Kruskal-Wallis test","volume":"611","author":"Ostertagova","year":"2014","journal-title":"Appl. Mech. Mater."},{"key":"10.1016\/j.psychres.2025.116406_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.psychres.2025.116406_bib0055","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1183912","article-title":"Cariprazine for negative symptoms in early psychosis: a pilot study with a 6-month follow-up","volume":"14","author":"Pappa","year":"2023","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116406_bib0056","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3389\/fpsyt.2019.00210","article-title":"Treatment-resistant to antipsychotics: a resistance to everything? Psychotherapy in treatment-resistant schizophrenia and nonaffective psychosis: a 25-year systematic review and exploratory meta-analysis","volume":"10","author":"Polese","year":"2019","journal-title":"Front. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2025.116406_bib0057","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00213-007-0731-1","article-title":"Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study","volume":"192","author":"Poyurovsky","year":"2007","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.psychres.2025.116406_bib0058","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0924-977X(02)00155-4","article-title":"Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study","volume":"13","author":"Poyurovsky","year":"2003","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"11","key":"10.1016\/j.psychres.2025.116406_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20110","article-title":"Clinical effectiveness and cost-effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia: a multicentre randomised controlled trial","volume":"20","author":"Priebe","year":"2016","journal-title":"Health Technol. Assess. (Rockv)"},{"issue":"4","key":"10.1016\/j.psychres.2025.116406_bib0060","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.4088\/JCP.13m08853","article-title":"Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials","volume":"75","author":"Rabinowitz","year":"2014","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2025.116406_bib0061","doi-asserted-by":"crossref","first-page":"A12","DOI":"10.7326\/ACPJC-1995-123-3-A12","article-title":"The well-built clinical question: a key to evidence-based decisions","volume":"123","author":"Richardson","year":"1995","journal-title":"ACP J. Club"},{"key":"10.1016\/j.psychres.2025.116406_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104979","article-title":"Thirty years of research on negative symptoms of schizophrenia: a scientometric analysis of hotspots, bursts, and research trends","volume":"144","author":"Sabe","year":"2023","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"5","key":"10.1016\/j.psychres.2025.116406_bib0063","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Med."},{"issue":"1","key":"10.1016\/j.psychres.2025.116406_bib0064","doi-asserted-by":"crossref","DOI":"10.1038\/s41537-021-00181-0","article-title":"Cognitive, creative, functional, and clinical symptom improvements in schizophrenia after an integrative cognitive remediation program: a randomized controlled trial","volume":"7","author":"Sampedro","year":"2021","journal-title":"NPJ Schizophr."},{"issue":"1","key":"10.1016\/j.psychres.2025.116406_bib0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/HRP.0000000000000184","article-title":"The prevalence of negative symptoms across the stages of the psychosis continuum","volume":"27","author":"Sauv\u00e9","year":"2019","journal-title":"Harv. Rev. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2025.116406_bib0066","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41398-023-02373-x","article-title":"Medication adherence and cognitive performance in schizophrenia-spectrum and bipolar disorder: results from the PsyCourse Study","volume":"13","author":"Senner","year":"2023","journal-title":"Transl. Psych."},{"issue":"3\/4","key":"10.1016\/j.psychres.2025.116406_bib0067","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2307\/2333709","article-title":"An analysis of variance test for normality (complete samples)","volume":"52","author":"Shapiro","year":"1965","journal-title":"Biometrika"},{"key":"10.1016\/j.psychres.2025.116406_bib0068","unstructured":"Sharpe, D., 2015. Chi-square test is statistically significant: now what? practical assessment, research, and evaluation 20 (1), 8."},{"issue":"12","key":"10.1016\/j.psychres.2025.116406_bib0069","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.biopsych.2011.06.021","article-title":"A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents","volume":"70","author":"Singh","year":"2011","journal-title":"Biol. Psych."},{"issue":"1","key":"10.1016\/j.psychres.2025.116406_bib0070","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s41811-023-00156-2","article-title":"Efficacy of cognitive training program given to patients with schizophrenia using computer tablets: a preliminary study","volume":"16","author":"Singh","year":"2023","journal-title":"Int. J. Cogn. Ther."},{"issue":"9","key":"10.1016\/j.psychres.2025.116406_bib0071","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.euroneuro.2013.03.006","article-title":"The impact of trial characteristics on premature discontinuation of antipsychotics in schizophrenia","volume":"23","author":"Spineli","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2025.116406_bib0072","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1176\/ajp.2007.164.3.415","article-title":"Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study","volume":"164","author":"Stroup","year":"2007","journal-title":"Am. J. Psych."},{"issue":"3","key":"10.1016\/j.psychres.2025.116406_bib0073","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4300\/JGME-D-12-00156.1","article-title":"Using effect size\u2014or why the P value is not enough","volume":"4","author":"Sullivan","year":"2012","journal-title":"J. Grad. Med. Educ."},{"key":"10.1016\/j.psychres.2025.116406_bib0018","series-title":"The Maudsley prescribing guidelines in psychiatry","author":"Taylor","year":"2021"},{"key":"10.1016\/j.psychres.2025.116406_bib0074","series-title":"GIMP","author":"Team","year":"2019"},{"key":"10.1016\/j.psychres.2025.116406_bib0075","article-title":"Assessment of noninvasive brain stimulation interventions for negative symptoms of schizophrenia: a systematic review and network meta-analysis","author":"Tseng","year":"2022","journal-title":"JAMA Psych."},{"key":"10.1016\/j.psychres.2025.116406_bib0076","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.genhosppsych.2015.11.008","article-title":"Prevalence and predictors of treatment dropout from physical activity interventions in schizophrenia: a meta-analysis","volume":"39","author":"Vancampfort","year":"2016","journal-title":"Gen. Hosp. Psych."},{"issue":"3","key":"10.1016\/j.psychres.2025.116406_bib0077","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1017\/S0033291714001147","article-title":"Adapted cognitive\u2013behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression","volume":"45","author":"Velthorst","year":"2015","journal-title":"Psychol. Med."},{"issue":"1\u20133","key":"10.1016\/j.psychres.2025.116406_bib0078","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.schres.2010.04.003","article-title":"Meta-analysis of rates of drop-out from psychosocial treatment among persons with schizophrenia spectrum disorder","volume":"121","author":"Villeneuve","year":"2010","journal-title":"Schizophr. Res."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125000551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125000551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:53:27Z","timestamp":1762250007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178125000551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":78,"alternative-id":["S0165178125000551"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116406","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and synthesis of 489 studies investigating treatments for negative symptoms in the schizophrenia spectrum: Trial designs, demographics and clinical characteristics","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116406","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116406"}}